Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease

Neurochemistry International

Volumn 55, Issue 6, 2009, Pages 369-375

  Verma, Ranjeet ^a   Nehru, Bimla ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Centrophenoxine; Dopamine; Oxidative stress; Parkinson's disease; Rotenone

Indexed keywords

CATALASE; CITRULLINE; DOPAMINE; GLUTATHIONE; MECLOFENOXATE; NITRIC OXIDE; ROTENONE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN DAMAGE; CEREBELLUM; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; HISTOPATHOLOGY; LIPID PEROXIDATION; MALE; MESENCEPHALON; MOTOR DYSFUNCTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; CEREBELLUM; CEREBRAL CORTEX; CYTOPROTECTION; DISEASE MODELS, ANIMAL; MALE; MECLOFENOXATE; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; SUBSTANTIA NIGRA; UNCOUPLING AGENTS;

ANIMALIA; RATTUS; RODENTIA;

EID: 67650094606     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.04.001     Document Type: Article

References (50)

1. Alam M., Mayarhofer A., and Schmidt W.J. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by l-DOPA. Behav. Brain Res. 151 (2004) 117-124
2. Alam Z.I., Daniel S.E., Lees A.J., Marsden C.D., Jenner P., and Halliwell B. A generalized increase in protein carbonyls in the brain in Parkinson's but not Incidental Lewy Body disease. J. Neurochem. 69 (1997) 1326-1329
3. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., et al. Oxidative DNA damage in the parkinsonian brain, a selective increase in 8-hydroxyguanine in substantia nigra?. J. Neurochem. 69 (1997) 1196-1203
4. Bashkatova V., Alam M., Vanin A., and Schmidt W.J. Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. Exp. Neurol. 186 (2004) 235-241
5. Betarbet R., Sherer T.B., MacKenzie G., Garcia-osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
6. Bhalla P., and Nehru B. Modulatory effects of centropheoxine in different regions of rat brain. Exp. Gerontol. 40 (2005) 801-806
7. Bishnoi M., Chopra K., and Kulkarni S.K. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur. J. Pharmacol. 552 1-3 (2006) 55-66
8. Boyde T.R.C., and Rahmatullah M. Optimization of conditions for the colorimetric determination of citrulline, using diacetly monoxime. Anal. Biochem. 107 (1980) 424-431
9. Chance B., Sies H., and Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 3 (1979) 527-605
10. Chen L., Ding Y., Cagniard B., Van Laar A.D., Mortimer A., Chi W., Hastings T.G., Kang U.J., and Zhuang X. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 28 2 (2008) 425-433
11. Chiueh C.C., Miyake H., and Peng M. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced Parkinsonism. Adv. Neurol. 60 (1993) 251-258
12. Church W.H. Column chromatography analysis of brain tissue: an advanced laboratory exercise for neuroscience majors. J. Undergrad. Neurosci. Educ. 3 (2005) A36-A41
13. Costall B., and Naylor R.J. On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacologia 34 3 (1974) 233-241
14. Dexter D.T., Carter C.J., Wells F.R., et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52 (1989) 381-389
15. Dexter D.T., Holley A.E., Flitter W.D., et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9 (1994) 92-97
16. Fossati P., Galibert P., Lopez-pinto C., Pruvot P., Pruvot-brulin J., Arnott, Laine E., and Linquette M. Centrophenoxine in the resuscitation of cranium-injured patients. Lille Med. 7 (1962) 500-506
17. Good P.F., Olanow C.W., and Perl D.P. Neuromelanin-containing neurons of the substantial nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593 (1992) 343-346
18. Halliwell B., and Gutteridge J. Oxygen radicals and the nervous system. Trends Neurosci. 8 (1985) 22-29
19. Hobbs A.J., Higgs A., and Moncada S. Inhibition of nitric oxide synthase as a potentail therapeutic target. Ann. Rev. Pharmacol. Toxicol. 39 (1999) 191-220
20. Humanson G.L. In: Animal tissue technique (1962), W.H. Freeman, San Francisco pp. 3-126
21. Jenner P., and Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 (1996) 161-170
22. Kenneth B.B., and Bruce N.A. The free radical theory of aging matures. Physiol. Rev. 78 (1998) 547-581
23. Kono Y. Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay of superoxide dismutase. Arch. Biochem. Biophys. 186 (1978) 189-195
24. Kulisiewicz T.A. Evaluation of the effect of Lucidril (ANP 235, centrophenoxine) "Bracco" in some organic nervous diseases and in chronic alcoholism. Pol. Tyg Lek 26 (1965) 969-972
25. Lapointe N., St-Hilaire M., Martinoli M.G., Blanchet J., Gould C.R., and Cicchetti F. Rotenone induces non-specific central nervous and systemic toxicity. FASEB J. 18 (2004) 717-719
26. Liao Y., Wang R., and Tang X.C. Centrophenoxine improves chronic cerebral ischemia induced cognitive deficit and neuronal degeneration in rats. Acta Pharmacol. Sin. 12 (2004) 1590-1596
27. Lincoln J., Hoyle C.H.V., and Burnstock G. Nitric Oxide in Health and Disease: Biochemical Research Topics (1997), Cambridge University Press, Cambridge, UK
28. Liu Y., Fiskuma G., and Schubert D. Generation of reactive oxygen species by the mitochondrial electron transport chain. J. Neurochem. 80 (2002) 780-787
29. Lotharius J., and O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275 (2000) 38581-38588
30. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with Follin-phenol reagent. J. Biol. Chem. 193 (1951) 265-275
31. Luck H. Catalase Spectrophotometric Method. Methods in Enzymatic Analysis (1963), Academic Press, New York
32. Moron M.S., Depierre J.W., and Mannervick B. Levels of glutathione, glutathione reductase and glutathione-s-transferase activities in rat lung and liver. Biochem. Biophys. Acta 538 (1979) 567-578
33. Nandy K. Centrophenoxine: effects on aging mammalian brain. J. Am. Ger. Soc. 26 (1978) 74-81
34. Nehru B., Bhalla P., and Garg A. Evidence for Centrophenoxine as a protective drug in aluminium induced behavioural and biochemical alteration in rat brain. Mol. Cell. Biochem. 290 (2006) 33-42
35. Nehru B., Verma R., Khanna P., and Sharma S.K. Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine. Brain Res. 1201 (2008) 122-127
36. Raddassi K., Berthon B., Petit J.F., and Lemaire G. Role of calcium in the activation of mouse peritoneal macrophages: induction of NO synthase by calcium ionophores and thapsigargin. Cell. Immunol. 153 (1993) 443-455
37. Roy D., et al. Effect of centrophenoxine on the antioxidative enzymes in various regions of the aging rat brain. Exp. Gerontol. 18 (1983) 185-197
38. Saravanan K.S., Sindhu K.M., and Mohanakumar K.P. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J. Pineal Res. 42 3 (2007) 247-253
39. Saravanan K.S., Sindhu K.M., Senthilkumar K.S., and Mohanakumar K.P. l-Deprenyl protects against rotenone-induced, oxidative stress mediated dopaminergic neurodegeneration in rats. Neurochem. Int. 49 (2006) 28-40
40. Schapira A.H.V. Present and future drug treatment for Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 76 (2005) 1472-1478
41. Schulz J.B., Henshaw D.R., Matthews R.T., and Beal M.F. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp. Neurol. 132 2 (1995) 279-283
42. Sherer T.B., Richardson J.R., Testa C.M., Seo B.B., Panov A.V., Yagi T., Matsuno-Yagi A., Miller G.W., and Greenamyre J.T. Mechanism of toxicity of pesticides acting at complex 1: relevance to environmental etiologies of Parkinson's disease. J. Neurochem. 100 6 (2007) 1469-1479
43. Shrerer T.B., Betarberbet R., Tasta C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Yagi A.M., and Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 340 (2003) 10756-10764
44. Stancheva S.L., and Alova L.G. Effect of centrophenoxine, piracetam and aniracetam on the monoamine oxidase activity in different brain structures of rats. Farmakol. Toksikol. 51 3 (1988) 16-18
45. Wills E.D. Mechanism of lipid peroxide formation in animal tissue. Biochem. J. 99 (1966) 667-676
46. Yong R.R., Wenhua L., Houbo J., Qian J., and Jian F. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 280 (2005) 34105-34112
47. Zhou J., and Tang X.C. Pharmacological effects of centrophenoxine and its potential therapy in Alzheimer's disease. Shanghai Med. Pharm. J. 22 (2001) 345-351
48. 2 release at mitochondria complex-1. J. Biol. Chem. 280 16 (2005) 15587-15594
49. Zs-Nagy I. A survey of the available data on a new nootropic drug, BCE-001. Ann. NY Acad. Sci. 717 (1994) 102-114
50. Zs-Nagy I., and Semsei I. Centrophenoxine increases the rates of total and mRNA synthesis in the brain cortex of old rats: an explanation of its action in terms of the membrane hypothesis of aging. Exp. Gerontol. 19 (1984) 171-178